Podcasts about Hazard

Today on the Woody and Wilcox Show: Things stuck in your body; Fun With Golf Audio; Woman claims she was not allowed on a ride at Disney because of what she was wearing; The Ataris released an album with ashes of a band member's father in the vinyl; Dukes of Hazard actor has passed away; Woody's Tom Wopat story; Pilots are encouraged to fart in front of each other; Chelsea and a listener have dreams about Wilcox's death; And more!

Acey Baby is BACK on the Limitless Wrestling Podcast! Josh & Randy are joined by the former Limitless Wrestling World Champion to talk his weight loss of 200+lbs, Wrestling Day @ Long Creek Youth Development, his road ahead in wrestling + much more! We also dive into a full preview of Saturday's BEERLY LEGAL which has been moved from Portland, ME to our home base at the Yarmouth Amvets Hall due to weather! ON THE CARD: - Limitless Championship: Channing Thomas vs. Gabby Forza - VLC Qualifier: Bear Bronson vs. Alec Price - VLC Qualifier: Aaron Rourke vs. Zak Patterson - VLC Qualifier: Aiden Aggro w/ J-Heru vs. Milo Mirra - Scotty 2 Hotty, Keagan Garland & Ace Romero vs. Swipe Right + Jose Zamora - 23 HAZARD vs. Seabass Finn - Dezmond Cole vs. Anthony Greene

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

A lil ol' cinnamon roll of a heroine enters the chat. Time for a real superwoman to roll up her sleeves and save Dora. Please go back and listen to Part One to catch up on just who the hell "Dr." Linda Hazard is and just how sadistic her "expertise" on fasting gets. Part Two of Three. Support our show and unlock tons of exclusive episodes on Patreon or Spotify.Hit us up on YouTube.Hit us up on Instagram.Hit us up on TikTok.Subscribe to our Free Substack to get new episodes emailed to you directly.Feel free to buy us a beer, or coffee, or pizza, or anything. Many thanks!Researched, written and hosted by Muriel.Produced and co-hosted by Nick.Info: www.murielsmurders.com

We speak with podiatrist Liam McManus and RW columnist Sophie Raworth about some of the potential risks of wearing supershoes – and what runners can do to mitigate this. Join Runner's World Club today: https://www.runnersworld.com/uk/podcastoffer Learn more about your ad choices. Visit megaphone.fm/adchoices

Crestline Chamber of Commerce Board Members Dirk Rinker and Nathan Hazard discuss Jamboree Days and the Corks n Hops Festival.

Join us every Sunday morning at 9:30 or 11.

Join us every Sunday morning at 9:30 or 11.

GOŚCIEM WYWIADU BYŁ DAMIAN SMYK DZIENNIKARZ GOAL.PL, NIEGDYŚ WESZŁO. PRZEZ LATA BYŁ BLISKO LECHA, WIĘC BYŁA OKAZJA POROZMAWIAĆ O KULISACH ZDOBYCIA MISTRZOSTWA DLA KOLEJORZA. PO WIĘCEJ ROZWIŃ OPIS______________________________________________________________⭐️ PARTNEREM KANAŁU JEST LEGALNY POLSKI BUKMACHER LEBULL

This episode of Heartbeat of Humanity is the fourth and last episode in a mini-series about the mental health of children and young adults in the contexts of emergencies or conflict with child and adolescent psychiatrist Brett McDermott.In this episode, MHPSS Adviser Arz Stephan talks to Brett  about who among children  and adolescents - or people in general - need further support following a natural hazard.Brett is an Australian child and adolescent psychiatrist. He is head of Tasmania's Child and Adolescent Mental Health Service and professor at the University of Tasmania. Brett has led several post-disaster programs in Australia to better support young people experiencing the trauma of floods, cyclones, bushfires and storms. His approach has influenced post-disaster interventions globally.Brett is currently a visiting scholar at the MHPSS hub. 

Old timey doctor - the lady version! A story so right for this podcast it's almost impossible to believe it's true. But it is. And sickening too. Plus it takes place in and around Seattle, pretty much exactly where Nick and Muriel spent their childhood and early adulthood. Also, her name truly, actually, is Dr. Hazard. RIPs no doubt. Full video of this episode up now on YouTube.Support our show and unlock tons of exclusive episodes on Patreon or Spotify.Hit us up on YouTube.Hit us up on Instagram.Hit us up on TikTok.Subscribe to our Free Substack to get new episodes emailed to you directly.Feel free to buy us a beer, or coffee, or pizza, or anything. Many thanks!Researched, written and hosted by Muriel.Produced and co-hosted by Nick.Info: www.murielsmurders.com

We'll meet some workers from the Philippines who are processing crab in St. Mary's + From 2023 we'll hear some of CBC Investigates coverage of the rotting fish sauce plant in St. Mary's + MHA Sherry Gambin-Walsh on why it's taken so long to help St. Mary's with the abandoned seafood sauce plant.

Join us Sundays at 9:30 or 11.

Join us Sundays at 9:30 or 11.

On today's show we are talking about new dangers in apartment buildings that have not been fully handled in the design of buildings or the building code. Certain metals produce their own fuel once ignited. You probably have done the science experiment of lighting a piece of magnesium wire on fire. Once lit, you can put this piece of burning wire into a tub of water and it will keep burning. The conventional wisdom in fire fighting is that if you have a fire, then the fastest way to put it out is to remove its source of oxygen. But what happens when the fire produces its own oxygen and the chemical reaction continues no matter what you do? Have you ever wondered why fireworks don't go out even if it's raining? Once a firework is lit, it will continue to burn until all of the fuel is expended. Now imagine if the fire is in the underground garage in your apartment building, or perhaps in the bicycle storage room next to the lobby of your building. Those electric bicycles are now a new type of fire hazard that didn't exist a few years ago. The electric vehicles are a new type of fire hazard that didn't exist a few years ago. When I look at the risks in a building, I believe that the bicycle room represents an equal if not a greater fire risk than the garage. In many cases, charging is being retrofitted into buildings that were never designed to have electric vehicles. This is something that you as a building owner need to become educated about and take real steps to mitigate that risk. --------------**Real Estate Espresso Podcast:** Spotify: [The Real Estate Espresso Podcast](https://open.spotify.com/show/3GvtwRmTq4r3es8cbw8jW0?si=c75ea506a6694ef1)   iTunes: [The Real Estate Espresso Podcast](https://podcasts.apple.com/ca/podcast/the-real-estate-espresso-podcast/id1340482613)   Website: [www.victorjm.com](http://www.victorjm.com)   LinkedIn: [Victor Menasce](http://www.linkedin.com/in/vmenasce)   YouTube: [The Real Estate Espresso Podcast](http://www.youtube.com/@victorjmenasce6734)   Facebook: [www.facebook.com/realestateespresso](http://www.facebook.com/realestateespresso)   Email: [podcast@victorjm.com](mailto:podcast@victorjm.com)  **Y Street Capital:** Website: [www.ystreetcapital.com](http://www.ystreetcapital.com)   Facebook: [www.facebook.com/YStreetCapital](https://www.facebook.com/YStreetCapital)   Instagram: [@ystreetcapital](http://www.instagram.com/ystreetcapital)  

In this episode of Heartbeat of Humanity, MHPSS Adviser Arz Stephan talks to Brett McDermott about how parents and caregivers can help children get through the first year after a natural hazard.Brett is an Australian child and adolescent psychiatrist. He is head of Tasmania's Child and Adolescent Mental Health Service and professor at the University of Tasmania. Brett has led several post-disaster programs in Australia to better support young people experiencing the trauma of floods, cyclones, bushfires and storms. His approach has influenced post-disaster interventions globally.Brett is currently a visiting scholar at the MHPSS hub. This episode of Heartbeat of Humanity is the third in a four-episode mini-series about the mental health of children and young adults in the contexts of emergencies or conflict.

Na Ukrajine je to dnes "Kto z koho". Rusko sa vydalo cestou opotrebovávajúcej vojny. V nej zvíťazí ten, kto bude schopný v tomto konflikte vydržať dlhšie. Tá vojnová línia sa dnes vedie medzi imperiálnym Ruskom a Ukrajinou podporovanou našou euroatlantickou civilizáciou. Tvrdí bývalý diplomat Peter Weiss. Podľa neho Rusku ide aj o rozloženie EÚ a NATO a preto je postoj Ficovej vlády iracionálnym hazardom s našimi národnoštátnymi záujmami.Ani druhé kolo priamych Rusko Ukrajinských rokovaní, ktoré sa včera uskutočnilo v Istanbule neprinieslo žiadny posun k ukončeniu ruskej agresie na Ukrajine. Návrhy, ktoré Rusko predložilo sú zjavne pre Ukrajinu neprijateľné a navyše, krátko predtým podnikli Ukrajinci bezprecedentný a úspešný dronový útok na strategické ruské letectvo hlboko v tyle nepriateľa. Táto vojna bude nadlho a bude to - kto z koho, teda či dlhšie vydrží Rusko alebo Ukrajina podporená našou euroatlantickou civilizáciou, hovorí pre Aktuality Nahlas exdiplomat Peter Weiss Zatiaľ čo vojna na Ukrajine nemá konca, slovenská zahraničná politika čoraz viac zapadá do pasce dvojtvárnosti a populistického alibizmu. Na jednej strane sa náš premiér ostentatívne chodí klaňať do Kremľa a vedie prázdne reči o mieri, na strane druhej sa zo Slovenska stáva zbrojárska veľmoc a naša vláda nemá pre našich kľúčových západných spojencov pekného slova. Do sporu sme sa dostali už aj s novým nemeckým kancelárom, ktorý nám pohrozil stopnutím eurofodov. Odpoveďou sú mu reči o fírerovi či volanie po vystúpení z EÚ. Kritika sa skrátka vo vládnej koalícií akosi nenosí. Počúvate Aktuality Nahlas, dnes o aktuálnom vývoji v mierových rokovaniach medzi Ruskom a Ukrajinou, ale aj o čudnej suverenite Ficovej zahraničnej politiky, ktorá podľa kritikov začína zásadne ohrozovať strategické záujmy krajiny. O čo teda Robertovi Ficovi vlastne ide a má ešte pod kontrolou nielen to, čo sa mu v tejto krajine deje, ale i to, aký obraz Slovensko dnes vysiela do sveta? A je niekde v pozadí "hra patriotov" o vyviazaní Slovenska zo zväzku Európskej únie? Témy pre bývalého diplomata a expredsedu SDĽ Petra Weissa.Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

Na Ukrajine je to dnes "Kto z koho". Rusko sa vydalo cestou opotrebovávajúcej vojny. V nej zvíťazí ten, kto bude schopný v tomto konflikte vydržať dlhšie. Tá vojnová línia sa dnes vedie medzi imperiálnym Ruskom a Ukrajinou podporovanou našou euroatlantickou civilizáciou. Tvrdí bývalý diplomat Peter Weiss. Podľa neho Rusku ide aj o rozloženie EÚ a NATO a preto je postoj Ficovej vlády iracionálnym hazardom s našimi národnoštátnymi záujmami.Ani druhé kolo priamych Rusko Ukrajinských rokovaní, ktoré sa včera uskutočnilo v Istanbule neprinieslo žiadny posun k ukončeniu ruskej agresie na Ukrajine. Návrhy, ktoré Rusko predložilo sú zjavne pre Ukrajinu neprijateľné a navyše, krátko predtým podnikli Ukrajinci bezprecedentný a úspešný dronový útok na strategické ruské letectvo hlboko v tyle nepriateľa. Táto vojna bude nadlho a bude to - kto z koho, teda či dlhšie vydrží Rusko alebo Ukrajina podporená našou euroatlantickou civilizáciou, hovorí pre Aktuality Nahlas exdiplomat Peter Weiss Zatiaľ čo vojna na Ukrajine nemá konca, slovenská zahraničná politika čoraz viac zapadá do pasce dvojtvárnosti a populistického alibizmu. Na jednej strane sa náš premiér ostentatívne chodí klaňať do Kremľa a vedie prázdne reči o mieri, na strane druhej sa zo Slovenska stáva zbrojárska veľmoc a naša vláda nemá pre našich kľúčových západných spojencov pekného slova. Do sporu sme sa dostali už aj s novým nemeckým kancelárom, ktorý nám pohrozil stopnutím eurofondov. Odpoveďou sú mu reči o fírerovi či volanie po vystúpení z EÚ. Kritika sa skrátka vo vládnej koalícií akosi nenosí. Počúvate Aktuality Nahlas, dnes o aktuálnom vývoji v mierových rokovaniach medzi Ruskom a Ukrajinou, ale aj o čudnej suverenite Ficovej zahraničnej politiky, ktorá podľa kritikov začína zásadne ohrozovať strategické záujmy krajiny. O čo teda Robertovi Ficovi vlastne ide a má ešte pod kontrolou nielen to, čo sa mu v tejto krajine deje, ale i to, aký obraz Slovensko dnes vysiela do sveta? A je niekde v pozadí "hra patriotov" o vyviazaní Slovenska zo zväzku Európskej únie? Témy pre bývalého diplomata a expredsedu SDĽ Petra Weissa.Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský

The Choking Hazard Podcast - Episode 95 - GTA 6 Thoughts, Dad Life, Business Owners & More!More Podcast Content: https://broughy.com/podcastSee all podcast episodes as videos in this playlistContributors[Host] Broughy1322: https://broughy.com[Co-Host] Sugar Free Nos: https://twitch.tv/sugar_free_nos[Co-Host] RDT33: https://twitch.tv/rdt33[Co-Host] Joshimuz: https://twitch.tv/joshimuz[Producer] MBHammer: https://twitch.tv/mbhammerTimestamps0:00:00 - Introduction0:01:49 - GTA VI Trailer 20:11:55 - Broughy's Parenting Report0:20:09 - Nos Owns A Dominos! And A New Car1:00:28 - Josh Hosted A GTAMarathon Event IRL1:24:38 - Twitch Deletes VOD Highlights1:32:42 - Gaming News1:42:49 - Racing Corner1:49:47 - Speedrun CornerPodcast pre-shows & gaming nights are all on https://youtube.com/ChokingHazardGaming

This is May 25th's sermon by Jason Cherry walking through the hazards pictured in Psalm 124 and the sins each address. Jason Cherry is an elder at Trinity Reformed Church, as well as a teacher and lecturer of literature, American history, and economics at Providence Classical School in Huntsville, Alabama. He graduated from Reformed Theological Seminary with an MA in Religion and is the author of the book The Culture of Conversionism and the History of the Altar Call, now available on Amazon. He is husband to Traci, who is proficient at blessing others, and father to Anily and Gaby, who are gifted in the art of laughter. Trinity Reformed Church is a CREC church in Huntsville, AL. seeking to extend and unite the Kingdom in the Huntsville area. Check out our website, Facebook or YouTube!

https://jo.my/9vvp4j Hazard Communication & Chemical Safety: Safe Handling, Storage, and Emergency Procedures Maintaining chemical safety in the workplace requires constant attention. Whether you're handling cleaning products, solvents, or industrial-grade chemicals, knowing how to work with hazardous materials safely is essential. Poor handling or storage can lead to serious incidents such as fires, spills, or harmful exposure. A strong Safety Culture ensures everyone understands their role in preventing these risks. This week focuses on safe handling, proper storage, and knowing how to respond if something goes wrong. Chemicals can be dangerous, but those risks are manageable with clear procedures and the right tools. Every team member plays a role in preventing accidents and protecting health and property. Here are a few tips to assist you with handling, storing, and responding to hazardous chemicals: Always wear the correct PPE. Ensure gloves, goggles, face shields, and respirators are available and worn as needed. Match the PPE to the type of chemical you're handling. Never assume standard gear is good enough—check the label or Safety Data Sheet (SDS). Store chemicals by compatibility. Never place acids near bases or oxidizers near flammables. Use labeled, ventilated storage cabinets designed for specific chemical types. Always keep containers closed and stored below eye level when possible. Keep spill kits nearby and ready. Train all employees on how to use them. If a spill occurs, act quickly but safely—evacuate if needed, contain the area, and report it immediately. Don't clean unless trained, and wear the correct PPE and equipment. Know the first aid procedures for each chemical. SDS sheets provide specific instructions for skin, eyes, or inhalation exposure. Make sure eyewash stations and showers are easy to reach and tested regularly. Prevent fire hazards and reactions. Keep ignition sources away from flammables. Bonding and grounding are used to treat flammable liquids during transfer. Monitor storage areas for heat or leaks, and never mix chemicals unless specifically trained and authorized. Creating a safe environment is about planning. That means having the right equipment, training, and clear emergency response steps. It also means speaking up if something looks wrong or out of place. Never ignore warning signs or bypass safety steps to save time. Chemical safety is everyone's responsibility. Follow procedures, use proper PPE, and take storage and emergency prep seriously. The right actions today prevent injuries and damage tomorrow. Thank you for being part of another episode of Warehouse Safety Tips. Until we meet next time - have a great week, and STAY SAFE! #Safety #SafetyFIRST #SafetyALWAYS #StaySafe #SafetyCulture #EmergencyPreparedness #SpillResponse #SafeStorage

Thank you so much for listening to the Bob Harden Show, celebrating nearly 14 years broadcasting on the internet. On Tuesday's show, we visit with Florida State Senator Kathleen Passidomo about the current extended legislative session to finalize the state budget. We visit with economics and political columnist Patrick Carroll about questions raised concerning the tariff agreement between the United State and the U.K about food standards. Boo Mortenson and I discuss the threat of “AI” to college education and the return to “blue book” exams. We also visit Linda Harden about the evidence of health hazards created by “5G.” Please join us tomorrow when we visit with Chairman Emeritus of Cato Institute Bob Levy and Professor Andrew Joppa. Access this or past shows at your convenience on my web site, social media platforms or podcast platforms.

Thank you so much for listening to the Bob Harden Show, celebrating nearly 14 years broadcasting on the internet. On Tuesday's show, we visit with Florida State Senator Kathleen Passidomo about the current extended legislative session to finalize the state budget. We visit with economics and political columnist Patrick Carroll about questions raised concerning the … The post Is “5G” a Public Health Hazard? appeared first on Bob Harden Show.

⚠️CAUTION⚠️ : King's Crossing!Seattle funny man, filth icon, and Emerald City King's Ball Grand Marquis Chance Hazard joins The Rewind. Let's dive into what drives his comedy, his art, and his overall goofy personality.You better be out there supporting Drag Kings! You can support Chance by clicking on his linktree: https://linktr.ee/ChanceHazardDragAnd support Thumali and Wayward World Studios: https://linktr.ee/waywardworldstudios

In this episode of Heartbeat of Humanity, MHPSS Adviser Arz Stephan talks to Brett McDermott about how parents and teachers can help children after a natural hazard.Brett is an Australian child and adolescent psychiatrist. He is head of Tasmania's Child and Adolescent Mental Health Service and professor at the University of Tasmania. Brett has led several post-disaster programs in Australia to better support young people experiencing the trauma of floods, cyclones, bushfires and storms. His approach has influenced post-disaster interventions globally.Brett is currently a visiting scholar at the MHPSS hub. This episode of Heartbeat of Humanity is the second in a four-episode mini-series about the mental health of children and young adults in the contexts of emergencies or conflict.

https://jo.my/ks9dzt Hazard Communication & Chemical Safety: GHS Labels and Pictograms Understanding how to correctly label chemicals and identify hazards is critical for keeping everyone in the facility safe. Week 3 of our Hazard Communication & Chemical Safety series focuses on labeling and pictograms, essential components of the Globally Harmonized System (GHS). A strong Safety Culture includes consistent, clear labeling and hazard recognition. It also relies on employees identifying the risks involved with each chemical or substance they handle. GHS labels are designed to communicate specific hazards quickly. They use standardized pictograms, signal words, hazard statements, and precautionary guidance. These labels are required on all primary containers and must stay intact and legible. Unfortunately, many accidents happen because labels are missing, unreadable, or incorrect. That's why clear and accurate labeling practices are key to chemical safety. Here are a few tips to assist you with proper labeling and understanding pictograms: Know the nine GHS pictograms. Each symbol represents a specific hazard. From the flame icon indicating flammable materials to the skull and crossbones for toxic substances, recognizing these symbols at a glance helps prevent unsafe exposure and improper handling. Always check for the six required elements on a GHS label. These include the product identifier, signal word, pictogram(s), hazard statement, precautionary statement, and supplier information. If any of these are missing, the label does not meet safety standards and should be reported. Label all secondary containers. If you transfer a chemical into a smaller or temporary container, it must also be labeled unless the person who moved it uses it immediately. That label should still include the product name and appropriate hazard information. Don't forget to ignore worn or damaged labels. Faded or peeling labels reduce the chance of proper identification. Replace them right away and report the issue to your supervisor. Use real-world examples to stay alert. Watch out for common mistakes, like handwritten labels missing hazard information or using abbreviations others may not understand. Ask or refer to the safety data sheet (SDS) when in doubt. Strong labeling practices don't just meet regulation requirements—they prevent injuries, reduce confusion, and help create a more organized and efficient facility. By taking time to review and understand labels and pictograms, you're actively helping to protect yourself and your team. Accurate labeling is not a suggestion. It's part of your responsibility to maintain a safe working environment. Let's make sure every label tells the whole story—and tells it. Thank you for being part of another episode of Warehouse Safety Tips. Until we meet next time – have a great week, and STAY SAFE! #Safety #SafetyFIRST #SafetyALWAYS #StaySafe #SafetyCulture #ChemicalSafety #GHSCompliance #HazardCommunication #LabelingMatters

Upřít lidem v zájmu demokracie demokratickou volbu lze jenom výjimečně. Je to trik průhledný, který se špatně opakuje. 19.05.2025, www.RadioUniversum.cz

Fortune favors the prepared!The Midwest Misfits aren't just a name—they're the real deal. On this episode of What's the Hazard, host Doug Fletcher goes behind the scenes with Nate, Cody, and Ryan to explore why rescue standby, industrial safety assessments, and hands-on confined space training are the future of workplace safety.If you've ever called 911 as your confined space rescue plan—you need to watch this episode.Awesome References:Children's Hospital: https://www.childrensomaha.orgBike With Mike: https://www.bikewithmikeday.com50 Mile March: https://50milemarch.orgReach out to the Misfits!mwmisfits.com(402)-984-8203Cody: cody.brdico@mwmisfits.comRyan: ryan.loewenstein@mwmisfits.comDoug Fletcher can be reached at doug@fletchersafety.comIf you have any topics you'd like Doug to address, feel free to reach out via email or shoot him a message on LinkedIMuch gratitude to our Sponsors and Supporters!Fallowich Construction Services: https://www.fallowichconstruction.comRockford Systems: https://rockfordsystems.com__________________________________This is another Hurrdat Media Production. Hurrdat Media is a podcast network and digital media production company based in Omaha, NE. Find more podcasts on the Hurrdat Media Network by going to HurrdatMedia.com or Hurrdat Media YouTube channel!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

https://jo.my/8fu6y7 Hazard Communication & Chemical Safety: Safety Data Sheets (SDS) A strong safety culture depends on clear communication, especially when it involves hazardous chemicals. That's where Safety Data Sheets (SDS) come in. These standardized documents are essential for informing, protecting, and preparing everyone in the facility. Understanding SDS is critical to chemical safety, whether you're handling a chemical daily or passing through a storage area. SDSs provide detailed information about the properties, hazards, safe handling, and emergency procedures related to chemical products used in your facility. Every worker has a right to know what chemicals are present, how they might be affected, and what steps to take in case of exposure. Knowing where to find SDSs and how to read them isn't just helpful—it's necessary. Here are a few tips to assist you with understanding and using Safety Data Sheets effectively: Know what an SDS is and why it matters: An SDS document provides key safety information about a chemical. It outlines how to store, handle, and dispose of the material safely and what to do in an emergency. These documents are standardized, making them easy to follow once you understand the format. Understand the structure of an SDS: Most SDSs are split into sections. These sections include identification, hazard identification, composition, first-aid measures, firefighting measures, handling and storage, exposure controls, and more. The first few sections are the most frequently used during daily tasks and emergencies. Always know where SDSs are located: They must always be easy to access, whether in a binder in the break room or through a digital system. Never guess when dealing with chemicals. If you can't find the SDS, stop and ask before proceeding. Use the SDS to prepare and respond: Whether using personal protective equipment, responding to a spill, or treating a chemical exposure, the SDS tells you what steps to take. It's the first line of defense in handling chemical-related incidents correctly. Remember your right to know: Every team member has the right to understand the hazards they may be exposed to. If you don't understand something in an SDS, ask questions. Staying informed helps keep everyone safe. Understanding how to read and use an SDS is not just for emergencies—it's part of working smart and staying safe daily. Make it a habit to review SDSs for any new chemical introduced into your area. To keep this knowledge fresh, reinforce it during toolbox talks and safety meetings. Your safety depends on preparation. With the correct information, you can minimize risks and create a safer work environment for everyone in the facility. Thank you for being part of another episode of Warehouse Safety Tips. Until we meet next time - have a great week, and STAY SAFE! #Safety #SafetyFIRST #SafetyALWAYS #StaySafe #SafetyCulture #ChemicalSafety #SafetyDataSheets #SDSAwareness

Contributor: Jorge Chalit-Hernandez, OMS3 Educational Pearls: Psychedelics are being studied for their therapeutic effects in mental illnesses, including major depressive disorder, post-traumatic stress disorder, anxiety, and many others Classic psychedelics include compounds like psilocybin, LSD, and ayahuasca MDMA and ketamine are often included in psychedelic research, but have a different mechanism of action than the others Their mechanism of action involves agonism of the 5HT2A receptor, among others Given their resurgence, there is an increase in recreational use of these substances A recent study assessed the risks of recreational users developing subsequent psychotic disorders Individuals who visited the ED for hallucinogen use had a greater risk of being diagnosed with a schizophrenia spectrum disorder in the following 3 years Hazard ratio (HR) of 21.32 After adjustment for comorbid substance use and other mental illness, the hazard ratio was 3.53 - still a significant increase compared with the general population They also found an elevated risk for psychedelics when compared to alcohol (HR 4.66) and cannabis (HR 1.47) The study did not assess whether patients received antipsychotics or other treatments in the ED References Lieberman JA. Back to the Future - The Therapeutic Potential of Psychedelic Drugs. N Engl J Med. 2021;384(15):1460-1461. doi:10.1056/NEJMe2102835 Livne O, Shmulewitz D, Walsh C, Hasin DS. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP. Addiction. 2022;117(12):3099-3109. doi:10.1111/add.15987 Myran DT, Pugliese M, Xiao J, et al. Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder. JAMA Psychiatry. 2025;82(2):142-150. doi:10.1001/jamapsychiatry.2024.3532 Summarized & Edited by Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

In our 100th episode, Annie gets Dave to watch a 1980s adaptation of a Barbara Cartland novel - yup, you read that right!   Contact us - willyoustillloveit@gmail.com   Many thanks, as ever, to Cambo for our theme music.

Arson and more undead threaten the lives of the party as well as some of the town's first settlers. Watch the video here: ⁠https://youtu.be/vr7Ubm60eOQ Join Troy Lavallee, Joe O'Brien, Skid Maher, Matthew Capodicasa, Sydney Amanuel, and Kate Stamas as they tour the country. Get your tickets today at ⁠https://hubs.li/Q03cn8wr0⁠. Access exclusive podcasts, ad-free episodes, and livestreams with a 30-day free trial with code "GCN30" at ⁠jointhenaish.com⁠. For more podcasts and livestreams, visit ⁠https://hubs.li/Q03cmY380⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

https://jo.my/erw5ze Hazard Communication & Chemical Safety: Introduction to Hazard Communication (HazCom) Our topic this month focuses on Hazard Communication, also known as HazCom. This standard is built on a simple principle: every team member has the right to know about the hazardous substances they may come into contact with during their shift. That includes how to handle them safely and what to do if something goes wrong. Hazardous chemicals, ranging from cleaning supplies to fuels, industrial solvents, paints, and everything in between, are present in nearly every facility. These substances can pose serious risks if not identified, stored, and communicated properly. A strong Safety Culture depends on everyone understanding these hazards and following safe practices. Here are a few tips to assist you with staying safe around hazardous chemicals: Know what's in your facility. All chemicals on site should be listed in a Safety Data Sheet (SDS), which must always be available to all team members. If you are unsure about a substance, check the SDS or ask a supervisor for guidance. Read the labels—every time. Before using any chemical, look at the label for hazard warnings, handling instructions, and required personal protective equipment (PPE). Never assume two similar-looking containers hold the same contents. Please follow the signage and posted instructions. Areas with chemical storage or usage will have signs indicating risks—flammable, corrosive, toxic, etc. Respect those warnings. They're there to prevent accidents before they happen. Wear the correct PPE for the job. Depending on the chemical involved, gloves, goggles, respirators, or protective clothing (To name a few) might be required. Using the correct PPE is a key part of protecting yourself from chemical exposure. Be sure to report damaged or missing labels. A label is your first line of defense. If labels are unreadable or missing, please treat the container as unknown and report it immediately. Don't try to guess what's inside. Hazard Communication is more than paperwork, posters, and labels—it's about making sure everyone in the facility understands the risks around them and knows how to act safely. It requires clear communication, consistent training, and a shared responsibility between leadership and staff. Building a safer workplace starts with knowledge. When everyone knows what substances are in use and how to interact with them safely, injuries and exposure incidents decrease. Make it a habit to check labels, read SDSs, and ask questions if something seems wrong. Thank you for being part of another episode of Warehouse Safety Tips. Until we meet next time - have a great week, and STAY SAFE! #Safety #SafetyFIRST #SafetyALWAYS #StaySafe #SafetyCulture #HazardCommunication #ChemicalSafety#PPE #HazCom #SDS #LabelItRight

Joining the Exchange is Jim McDougald, Assistant Deputy Director over Community Wildfire Preparedness and Risk Reduction at CAL FIRE.

Get ready for the funkiest episode of The Number Two Show yet! Rafe Williams sits down with Ryan and Pat from the legendary St. Louis funk band Hazard to Ya Booty to talk about their origin story, cosmic funk magic, and the strange connection between comedy and bass playing. Then they light up the studio with two incredible live performances: “Get the Gurney” and “Gimme That” — including the world premiere of their hot new single. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Get ready for the funkiest episode of The Number Two Show yet! Rafe Williams sits down with Ryan and Pat from the legendary St. Louis funk band Hazard to Ya Booty to talk about their origin story, cosmic funk magic, and the strange connection between comedy and bass playing. Then they light up the studio with two incredible live performances: “Get the Gurney” and “Gimme That” — including the world premiere of their hot new single. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Get ready for the funkiest episode of The Number Two Show yet! Rafe Williams sits down with Ryan and Pat from the legendary St. Louis funk band Hazard to Ya Booty to talk about their origin story, cosmic funk magic, and the strange connection between comedy and bass playing. Then they light up the studio with two incredible live performances: “Get the Gurney” and “Gimme That” — including the world premiere of their hot new single. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After a much-needed Easter Weekend off, the Kokomo Press Podcast is back with a two-hour long episode that's sure to reignite the flames of comedyHost Jordan Grainger is joined this week by recent foot model and co-host Cortni Richardson and the rest of our panel is "Straight Outta Geek Street"!Outhouse Records and Dwarf Among Midgets bandmembers Messy Gravis and Matty Crull joined the Press Studio to give us all a full recap of how they spent a week shut down by the Fire Marshall and how the entire process went down, including the great local business owners who stepped up to help.The Outhouse Super Show Hosts talked live shows including our partnership on a weekly Thursday Comedy Open Mic, but we also talked a ton of wacky news and crazy pop-culture stuff including Kanye, The Last of Us TV Show verses the game, Star Wars, Baseball, upcoming shows!The Panel was thorough and informative but also made time to goof off and talk a little trash per usual. You can check it all out right here on this special flame-retardant episode of, the Kokomo Press Podcast! @thekokomopress on YouTube, Facebook, and instagram.Jordan Grainger is @ultrajoyed on twitter, facebook, and tiktok.Jordan Bell is @hypocrisy_jones on all major platforms.Cortni Richardson is @cortni88 on instagram and @cortni_lean on twitter.Brian West is @veinypeckerpete on twitter and @westjr.brian on instagram.

With the NFL Draft looming large this weekend, we decided to take a spin on the format and bring it into the world of the Premier League.  What would it look like if we held an All-Time Premier League Draft? Which legends go first and can anyone build the perfect squad? Host: Duncan Alexander With: Jacob Whitehead, Oli Kay, and Jack Lang Executive Producer: Adey Moorhead Producer: Mike Stavrou & Liam Warburton Premier League Draft article: https://www.nytimes.com/athletic/6301841/2025/04/24/premier-league-draft/  Teams: Jacob: Cech, Azpilicueta, Van Dijk, Kompany, Baines, Rodri, Lampard, Silva, Salah, Rooney, Giggs Jack: Alisson, Walker, Ferdinand, Campbell, Irwin, Kante, Fabregas, De Bruyne, Hazard, Shearer, Henry Duncan: Ederson, Ferreira, Adams, Vidic, Robertson, Keane, Toure, Beckham, Bergkamp, Aguero, Suarez Oli: Schmeichel, Alexander-Arnold, Carvalho, Terry, Cole, Vieira, Gerrard, Scholes, Ronaldo, Kane, Bale Learn more about your ad choices. Visit megaphone.fm/adchoices

With the NFL Draft looming large this weekend, we decided to take a spin on the format and bring it into the world of the Premier League. What would it look like if we held an All-Time Premier League Draft? Which legends go first and can anyone build the perfect squad?Host: Duncan AlexanderWith: Jacob Whitehead, Oli Kay, and Jack LangExecutive Producer: Adey MoorheadProducer: Mike Stavrou & Liam WarburtonPremier League Draft article: https://www.nytimes.com/athletic/6301841/2025/04/24/premier-league-draft/ Teams:Jacob: Cech, Azpilicueta, Van Dijk, Kompany, Baines, Rodri, Lampard, Silva, Salah, Rooney, GiggsJack: Alisson, Walker, Ferdinand, Campbell, Irwin, Kante, Fabregas, De Bruyne, Hazard, Shearer, HenryDuncan: Ederson, Ferreira, Adams, Vidic, Robertson, Keane, Toure, Beckham, Bergkamp, Aguero, SuarezOli: Schmeichel, Alexander-Arnold, Carvalho, Terry, Cole, Vieira, Gerrard, Scholes, Ronaldo, Kane, Bale Hosted on Acast. See acast.com/privacy for more information.

On this episode of What's the Hazard, legal expert Justin High (partner at High & Younes) gives safety professionals a roadmap for:Workers' Comp Basics: No-fault coverage vs. full personal-injury lawsuitsThird-Party Suits: When you can sue the at-fault party in addition to your employerContingency Fees Explained: Why you never write a check, but still pay out of your recoveryCourtroom Myths: See how A Few Good Men stacks up against real trialsSubpoena Power & Spoliation: How to preserve evidence and avoid “adverse inferences”Just like the most-watched how-to videos on YouTube, Justin's practical tips will help you navigate legal hazards with confidence. Drop a

Gaspar tries to keep up as Stage Right Mike and Spunky Comstock recount their wild adventure to Codfish Hollow, Iowa, where they caught Craig Finn and Bob Mould performing together.* The guys describe their unconventional journey following directions that included "take a left at the cow pasture" and encountering a town crier dressed remarkably like Jesse Ventura from "Predator."* Mike and Spunky share how they tempted fate by visiting the Buddy Holly crash site the morning after seeing two iconic bespectacled frontmen perform. Spunky nicely ties Craig Finn to the "Dukes of Hazard" opening theme.* Gaspar and Mike offer their predictions and Wishlist's for opening acts at the upcoming Minnesota shows.* Mike provides his unique brand of travel advice for first-time visitors to Minnesota, including essential destinations, local customs, and food recommendations that may or may not be helpful.Send us a voicemail:https://www.speakpipe.com/TheHoodratRecapPodcastContact us:Thehoodratrecap.com

In this installment of the "WC Job Fair" series, we engage in a profound dialogue with Josh Patterson, a multifaceted individual whose professional journey has traversed the realms of pastoral leadership, brewing, and currently, hazard mitigation. The central theme of our conversation revolves around the intricate relationship between spiritual beliefs and everyday occupational practices. Patterson elucidates how the theological principles that permeate religious discourse bear a significant relevance to the quotidian experiences of individuals in various professions. He poignantly articulates the importance of fostering community connections, emphasizing that the challenges faced in one domain are often reflective of broader societal issues, thereby underscoring our collective responsibility. This episode serves as a salient reminder of the need for genuine engagement and mutual support within our communities, particularly in the context of emergency management and the vital work carried out by those in this field.In this thought-provoking episode of the Whole Church Podcast, listeners are treated to an engaging conversation with Josh Patterson, a multifaceted individual whose journey traverses the realms of pastoral ministry, brewing, and hazard mitigation. The discussion centers on the relevance of theological concepts traditionally debated within church contexts and their implications for everyday work life. Patterson's unique experiences serve as a lens through which the hosts explore the interrelation between faith and vocation, prompting a reevaluation of how spiritual beliefs manifest in professional settings.Patterson's narrative reveals how his background as a pastor informs his current role as a hazard mitigation projects officer, emphasizing the continuity of community-building and relational engagement across varied occupations. He articulates the idea that understanding one's work as an extension of one's faith can transform how individuals approach their daily responsibilities, urging listeners to recognize the spiritual significance of their labor. This episode invites reflection on the ways in which theological discussions can and should influence our actions within the workforce, highlighting the necessity of integrating faith into all aspects of life.Furthermore, the dialogue addresses the challenges and opportunities presented by contemporary societal issues, advocating for churches to engage more deeply with the realities faced by individuals in their professional lives. Patterson calls for a model of church that champions connection, support, and understanding, rather than one confined to doctrinal debates. This episode serves not only as a valuable resource for church leaders but also as an encouragement for all listeners to embody their faith through their work, fostering a culture of compassion and mutual upliftment in their respective communities.Takeaways: In this episode, Josh Patterson elucidates the profound connection between one's theological understanding and their everyday work experiences, particularly in fields outside traditional ministry. The conversation emphasizes the significance of community and support in both the church and workplace, highlighting that our neighbors' challenges ultimately affect us all. Josh's transition from the brewing industry to hazard mitigation illustrates how diverse experiences can shape one's faith and vocation, revealing the interconnectedness of all occupations. The episode explores the relevance of theological discussions, asserting that many topics debated in church may seem irrelevant to those outside the ministry, thus encouraging churches to engage with broader community issues. Listeners are reminded of the importance of being compassionate and supportive towards emergency management workers, as their roles are crucial in safeguarding communities during crises....

Subscriber-only episodeSend us a textIn this week's bonus episode, Amy draws a throughline between the 1970s-era Esquire magazine writing of Nora Ephron and the sharp-witted book reviews of Dorothy Parker. A recent McNally Editions collection of these reviews called Constant Reader: The New Yorker 1927-28 provides a perfect opportunity to explore Parker's opinions on some lost ladies of lit, from Zona Gale and Elinor Glyn to Fannie Hurst and Elinor Wylie. Which women earned Parker's praise and which drew her disdain? Listen to find out — (and be prepared to laugh!)Mentioned in this episode:Crazy Salad and Scribble Scribble: Some Things About Women and Notes on Media by Nora EphronConstant Reader: The New Yorker from 1927-28 by Dorothy ParkerLost Ladies of Lit Episode No. 126 on Elinor Glyn with Hilary A. HallettIt by Elinor GlynLost Ladies of Lit Episode No. 13 on Nathalia CraneLost Ladies of Lit Episode No. 69 on Margery Latimer with Joy CastroYellow Gentians and Blue by Zona GaleMr. Hodge and Mr. Hazard by Elinor WylieA President is Born by Fannie HurstIn the Service of the King by Aimee Semple McPhersonBeauty and the Beast by Kathleen NorrisFor episodes and show notes, visit: LostLadiesofLit.comSubscribe to our substack newsletter. Follow us on instagram @lostladiesoflit. Email us: Contact — Lost Ladies of Lit Podcast

Welcome to Season 3 of Texture Talks!

The federal government has been tracking the weather for more than 150 years. But the rise of the Internet and big tech have made weather forecasting a more crowded space. Today on the show, the value of an accurate forecast and how the Trump administration's early moves are clouding the government's future forecasting. This piece originally aired in November 2024. Related stories: Hazard maps: The curse of knowledge (Apple / Spotify) Should we invest more in weather forecasting? After a year of deadly weather, cities look to private forecasters to save lives Fact-checking by Sierra Juarez. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Dries Mertens sits down with our very own John Obi Mikel to discuss life in Turkey with Galatasaray. The Belgian forward also reflects on finally ending Napoli's 33 year wait for the Scudetto, explains why there was no problem with Eden Hazard in the Belgium set up and reserves special praise for team-mate Victor Osimhen. He may be 37 now, but Dries Mertens - Napoli's all-time leading goalscorer with 148 goals - still has plenty left to achieve in the game. Enjoy! https://www.instagram.com/obionepodcast?igsh=MWNzbHVocHdzeWZwdA== https://x.com/obionepodcast?s=21 https://www.facebook.com/share/1AJ7ZPB4Cp/?mibextid=wwXIfr Learn more about your ad choices. Visit megaphone.fm/adchoices

Nick has good intentions and is trying to promote a healthier lifestyle at his business. But, could Nick's good intentions lead him to a bad ending? Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nick has good intentions and is trying to promote a healthier lifestyle at his business. But, could Nick's good intentions lead him to a bad ending? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Jared's fresh off of a trip to Montreal, or as he calls it The Coldest Place on Earth, and comes back with hot takes about the food and one glowing restaurant recommendation. Then J&J gab about their recent trip to L.A. and the difference in hotness factor between Los Angeles and New York (Gremlin Swamp People unite!). They also reflect on a strange interaction they had with a recently divorced man at a bar.Later, we dive into emails and hear from a listener who feels that her boyfriend made a joke at her expense that went too far. On an Awkward Encounter that we'll never forget, a listener takes a chance going to a playoff hockey game with a guy she just met. Things take a turn when the “Mayor of Detroit” picks her up in a Dukes of Hazard themed golf cart and gets plastered at the game. Then a listener taps J&J for advice on a romantic connection where the physical isn't matching the emotional one. We end with a round Red Flag Deal Breaker about a forgotten vasectomy, a mean quote from a Rate My Professor review, and an aspiring “boy dad.” Have a dating question for Jordana and Jared? Send an email or voice memo to uup@betches.com or leave us a voicemail at our dating hotline 212-589-8903.  Learn more about your ad choices. Visit megaphone.fm/adchoices